scholarly journals The critical period

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
M. Birchwood

Aim:Evidence from long-term follow-up studies of schizophrenia and from the ‘new epidemiology’ of psychoses has forced us to rewrite the textbooks and challenge accepted wisdom. In this paper I aim to review the concept of my ‘Critical Period’ in the long-term trajectory of schizophrenia.Method:I will review long-term follow-up studies of first episode psychosis.Results:Studies suggest that:a.the course of the psychoses is very variable;b.much of this variability is laid down during the ‘prodromal’ and first 3 - 5 years following the first episode;c.the ‘disability’ plateaus quickly, much of it occuring before the positive symptoms develop (the ‘symptom-disability gap’) butd.the psychosocial and ecological risk factors that have now been uncovered, suggest a more protean, malleable process in the development of psychosis, as witnessed, for example by the considerable number of ‘at risk’ individuals with low-level, but disabling psychotic symptoms, who escape psychosis (the misnomer of the ‘false positive’).Conclusion:This picture presents a fresh take on my concept of the ‘critical period’ with implications for public health and prevention.

1995 ◽  
Vol 167 (5) ◽  
pp. 596-603 ◽  
Author(s):  
Peter Mason ◽  
Glynn Harrison ◽  
Cristine Glazebrook ◽  
Ian Medley ◽  
Tim Dalkin ◽  
...  

BackgroundThis paper describes the 13-year outcome of an epidemiologically defined and representative cohort of patients selected when they were experiencing their first episode of schizophrenia.MethodIn a 13-year follow-up study of a cohort identified in Nottingham in 1978–80, the outcome (symptoms, disability, residence and treatment) was assessed using standardised instruments.ResultsFour of the original 67 patients with ICD–9 schizophrenia were lost to follow-up and five were dead: 52% were without psychotic symptoms in the last two years of follow-up, 52% were without negative symptoms and 55% showed good/fair social functioning. However, only 17% were alive at follow-up, without symptoms and disability, and receiving no treatment.ConclusionsThe findings reported are similar to those of other long-term follow-up studies of schizophrenia and also to 5-year follow-up studies. Kraepelin's emphasis on the longitudinal implications of a diagnosis of schizophrenia are supported, but may be over-pessimistic.


2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S314-S314
Author(s):  
Nikolai Albert ◽  
Karl Ole Köhler-Forsberg ◽  
Carsten Hjorthøj ◽  
Merete Nordentoft

Abstract Background In studies investigating the relapse rate of psychotic symptoms in patients diagnosed with schizophrenia there is a discrepancy between discontinuation studies finding a relapse rate up to 90% after discontinuation of antipsychotic medication and long-term follow-up studies finding approx. 30% of patients living without antipsychotic medication and psychotic symptoms. Long-term follow-up studies often have multiple follow-up assessments, but little is known about the use of medication in the intervals between the follow-up points. While register studies can follow large cohorts of patients, they are unable to investigate psychopathology and level of functioning in patients who discontinue their medication. In this study we use data from a clinical cohort with information on participants symptoms and functioning and combine them with register data on the individual participants prescriptions and hospitalizations. Methods The present study represents a combination of a clinical study from early intervention settings and register-based information on antipsychotic drug use and hospital contacts. For the present study, patients were included 18 months into their 24 months early intervention treatment and followed up 3 ½ year later. At baseline and follow-up we performed clinical assessments with all patients and via the Danish National Hospital Register and the Danish National Prescription Register, we had complete nationwide information for all patients identifying all redeemed prescriptions for antipsychotic drugs from 6 to 42 months after inclusion into the study. Based on medication information from the Danish National Prescription Register, we divided participants in the following four groups: 1) Non-users, 2) compliant on medication, 3) stopped but resumed later with medication, and 4) stopped with medication. Results Of the 316 participants included in this study 94.3% had I diagnosis of schizophrenia. In the 3 years preceding the 5 years follow-up 28.2% did not redeem any prescriptions for antipsychotics drugs while 21.2% discontinued their treatment during the follow-up, 20.9% discontinued their treatment but resumed later and 29.7% remained in stable treatment. At the 5 years follow-up the 30.3% of the Never-users where in competitive employment, the mean psychotic symptom score were 1.4 SD (1.4) and negative symptoms 1.1 SD (0.9). Whiles these results were worse for patients Compliant on medication (17%, 1.9 SD (1.3), 1.8 SD (1.0)), Stopped but resumed medication (10.6%, 22.4 SD (1.4), 1.5 SD (1.0)) and Stopped medication (17%, 1.6 SD (1.3), 1.3 SD (1.0)), respectively. Of the Never-user 23.6% were in remission of both positive and negative symptoms, while this was only the case for 12.8% of those compliant on medication. Discussion This study is a naturalistic cohort study and we are unable to draw any conclusion regarding the causality between symptoms remission and use of antipsychotic medication. The study shows that a substantial proportion of patients, for several years, can discontinue their medical treatment without being re-hospitalized and with lower symptoms burden then patients who continue their medical treatment. Some patients discontinue their treatment but resume it later. These patients have approximately the same functional level and psychotypological scores as those who are compliant with their medical treatment and are treated with equivalent doses of antipsychotic at the time of the follow-up.


2014 ◽  
Vol 159 (1) ◽  
pp. 70-75 ◽  
Author(s):  
Kally Yuen ◽  
Susy M. Harrigan ◽  
Andrew J. Mackinnon ◽  
Meredith G. Harris ◽  
Hok Pan Yuen ◽  
...  

Author(s):  
Merete Nordentoft ◽  
Trine Madsen

This text summarizes the literature regarding suicide among people with psychosis. Psychotic disorders on schizophrenia spectrum are among the most severe psychiatric disorders, and are associated with a particularly high risk of suicide. Long-term follow-up studies have found that up to 6% of people with these disorders die from suicide. Young people with psychotic disorders have a 25-fold higher risk of suicide compared to age-matched people in the general population. Being recently diagnosed, an inpatient, or recently discharged from psychiatric with a psychotic disorder, all represent high-risk periods for suicide. Indicated prevention in these high-risk periods is crucial, but also selective interventions such as early detection and intensive treatment of first episode psychosis, have shown to have positive effects on suicidal behaviour. Moreover, universal interventions aimed at the whole population, such as restricting access to lethal means, are important to implement to prevent suicide in people with psychotic disorders.


Sign in / Sign up

Export Citation Format

Share Document